CVC units Brace Pharma Capital and MRL Ventures were among the investors as MiRagen took its total funding to $115m and agreed to acquire Signal Genetics.
Investors including pharmaceutical firms Merck & Co and EMS agreed to provide $40m of funding for US-based biopharmaceutical company MiRagen Therapeutics on Tuesday.
The corporates, which invested through their Brace Pharma Capital and MRL Ventures units respectively, were joined by Fidelity Management and Research Company, Atlas Venture, Boulder Ventures, Jafco, MP Healthcare Venture Management and Remeditex Ventures.
MiRagen is developing treatments for T-cell lymphoma and fibrosis that will work by targeting microRNA molecules. Two of its drug candidates are currently…
